• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

AAC Technologies Expects Group Revenue Growth of Over 18% in 2025, with a Gross Profit Margin Higher than 2024

PR Newswire by PR Newswire
27 August 2025
in PR Newswire
0
AAC Technologies Expects Group Revenue Growth of Over 18% in 2025, with a Gross Profit Margin Higher than 2024
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

SINGAPORE, Aug. 27, 2025 /PRNewswire/ — On August 21, AAC Technologies (2018.HK) released its 2025 interim results report in Singapore. The Group’s revenue for the first half was RMB 13.32 billion, a year-on-year increase of 18.4%, setting a new record high. Net profit surged by 63.1% year-on-year to RMB 876 million.

AAC Technologies CFO Guo Dan said that the Company’s revenue in the second half will continue to maintain a high year-on-year growth rate, which is expected to be no less than the above figure in the first half, and the gross profit margin for the whole year will be no less than 22.1% last year. With the trend of AI upgrades, multiple businesses such as heat dissipation products and MEMS microphones will double in growth, and in-vehicle product revenue and gross profit will achieve stable growth.

In addition, global shipments of proprietary WLG lenses will exceed 10 million units this year, with a projected 50% increase next year. As the mass production scale increases, the gross margin is expected to surpass that of plastic lenses, marking a milestone breakthrough.


The gross profit margin for acoustics for the full year will not be lower than 30.2% last year

Financial reports show that in the first half, the gross profit margin of the acoustics business of AAC Technologies was 27.2%, a year-on-year decrease of 2.7 percentage points. The business achieved revenue of RMB 3.52 billion, a year-on-year increase of 1.8%.

Dan stated that the slight fluctuation in the gross margin of acoustics, one of the Company’s traditional core businesses, was mainly due to the introduction of a large number of new product projects in the first half. As operational efficiency gradually improves in the second half and products enter large-scale mass production, the gross margin for acoustics will steadily increase. The Company’s annual gross margin for acoustics will remain at least as high as 30.2% last year.

In the first half of 2025, AAC Technologies launched a series of innovative acoustic products. The master-level super linear speakers (SLS) and coaxial speakers maintained their leadership in the mid-range to high-end market, with shipments exceeding 17 million units, representing an increase approaching 40% year-on-year. The Group introduced the first master-level coaxial symmetrical dual speaker and the thinnest speaker in the industry featuring a thickness of just 1.4 mm per unit.

WLG product stands to achieve a milestone breakthrough

In the first half of 2025, AAC Technologies’ optics business maintained its rapid growth momentum, with revenue of RMB 2.65 billion, a year-on-year increase of 19.7%. The gross profit margin for plastic lenses improved by more than 10 percentage points, and the gross profit margin for the whole year is expected to exceed 30%. With the rise in both volume and price brought about by the high-end upgrade of smartphones, there will be further room for growth next year.

AAC Technologies’ proprietary WLG technology performed exceptionally well and received positive market feedback. The Company secured orders for 1G6P lenses from several leading Chinese customers for their flagship models and exclusively supplied WLG-based ultra-light micro-prism solutions.

AAC Technologies’ WLG lens shipments will exceed 10 million units this year, with an expected growth of more than 50% next year. Dan said, “The unique performance advantages of WLG technology will bring profound changes to both customers and user experience, and a growth of more than 50% is certain.”

The Company has achieved a yield rate of over 80% in WLG technology and has already made WLG single lenses profitable. With further increases in mass production scale, the gross profit margin of G+P hybrid lenses is expected to reach or even exceed that of plastic lenses.

AI will drive double growth across multiple businesses

AAC Technologies will benefit significantly from the development of the AI industry, with multiple business segments achieving rapid growth. Due to the higher demand for voice interaction functions in AI smartphones, the MEMS microphone business will be the first to benefit, with revenue in 2025 expected to increase more than 50% compared to 2024.

Due to the higher computing power and greater power consumption of AI smartphones, the demand for heat dissipation performance is also increasing, which will directly drive the rapid growth of AAC Technologies’ heat dissipation business. The Company has secured orders from high-end overseas customers and expects to begin mass production smoothly in the second half of the year. The overall revenue scale of the heat dissipation product line in 2025 will exceed RMB 1.2 billion, at least tripling that of 2024.

In addition, the trend toward ultra-thin foldable phones will bring more market opportunities for AAC Technologies’ high-performance, high-density products, potentially driving continuous growth in the average selling price (ASP) of its innovative products, core components, and modules. It is expected that revenue from the acoustics business will continue to grow throughout 2025, with revenue from motor product business achieving double-digit growth.

Regarding the application of the side buttons module in iPhone, Dan stated that it would be inappropriate to comment on specific customers. In terms of its own products, AAC Technologies’ keypad module products began shipping at the end of last year, and the functionality of these products will undergo further refinement and evolution. The Company is capable of providing support to both Chinese and international customers.

In-vehicle product revenue and gross profit will achieve stable growth

In recent years, AAC Technologies has been actively developing its second growth curve. The Company entered the in-vehicle product field in 2021 and has continuously improved its business layout through the acquisitions of Premium Sound Solutions (PSS), and Hebei First Light Auto Parts Co., Ltd. It has developed system-level solution capabilities in areas such as speakers, algorithms and amplifiers.

AAC Technologies has rapidly entered the European, American, and China’s leading new-generation automakers through mergers and acquisitions, becoming a Tier 1 supplier. PSS has obtained a favorable design-win with overseas customers, especially mainstream European customers, and its revenue and gross profit will achieve stable growth. Revenue from the automotive acoustics business has accounted for more than 13% of the Group’s total revenue. The in-vehicle product business will expand from components to branded system products and the Company is expected to become a diverse solution provider integrating audio, video, and lighting.

Financial reports show that in the first half of 2025, AAC Technologies’ in-vehicle product business generated revenue of RMB 1.74 billion, a year-on-year increase of 14.2%, with a gross profit margin of 23.9%. The Group obtained a design-win of a flagship SUV of a Chinese new energy vehicle (NEV) brand, and the project features 32 speakers, 40-channel amplifiers, algorithms, and tuning services.

Regarding the hot topics of market concern, Dan said that based on the current situation, AAC Technologies’ growth rate in the second half of the year will be no lower than that in the first half, with annual revenue maintaining double-digit growth year-on-year and gross profit margin steadily improving. While achieving business growth, the Company has kept its research and development, sales, and management expenses at a reasonable level, which is a result of the Company’s transformation in recent years. The Company will actively seize market opportunities, expand its market share, achieve steady performance growth, continue to bring better returns to shareholders, and share the fruits of the Company’s development.

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
  • Trending
  • Comments
  • Latest
Tai Po fire death toll climbs to 44, 56 injured

Tai Po fire death toll climbs to 44, 56 injured

26 November 2025
No for now on women deacons, Vatican commission says

No for now on women deacons, Vatican commission says

4 December 2025

Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

23 November 2025
Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

4 November 2025
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025

Recent News

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com